Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING] (DING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03176407
Recruitment Status : Completed
First Posted : June 5, 2017
Results First Posted : October 10, 2019
Last Update Posted : October 10, 2019
Sponsor:
Information provided by (Responsible Party):
Ovesco Endoscopy AG

Brief Summary:

The clinical trial entitled "Detection of upper gastrointestinal (GI) bleeding with a novel bleeding sensor capsule - a pilot study" was carried out in a monocentric clinical trial with 30 patients. This trial aimed to determine if the capsule's sensor signals allow to deduct the patient's bleeding status in a clinical setting.

The target of the explorative study was to show the feasibility and safety of the HemoPill acute and its implementation procedure as well as, the definition of measurable parameters and thresholds for blood detection. Within this clinical trial, initial clinical data on the performance of the HemoPill acute capsule were collected.


Condition or disease Intervention/treatment Phase
Upper GI Bleeding Diagnostic Test: HemoPill acute Not Applicable

Detailed Description:

The clinical trial entitled "Detection of upper gastrointestinal (GI) bleeding with a novel bleeding sensor capsule - a pilot study" was carried out in a monocentric clinical trial with 30 patients as part of the final development phase of the HemoPill acute, a bleeding sensor capsule. The swallowable capsule operates with the combination of an optical sensor for blood detection positioned within a recess in the capsule surface and a radio interface for wireless transmission of sensor data to an external receiver device. The HemoPill acute capsule is used for diagnosis of patients with suspected acute upper gastrointestinal bleeding.

For the study, the HemoPill acute capsule was swallowed by the patient and a special extracorporeal receiver was positioned next to the patient's body. The receiver recorded sensor signals from the ingested capsule for the next 4 hours. Patients who had swallowed a capsule underwent endoscopy within the next 12 hours. Later, both the endoscopic pictures and the endoscopy report were compared to the sensor capsule data recorded in the extracorporeal receiver. Furthermore, the excretion of each HemoPill acute capsule was monitored in accordance with the study protocol (regular check to see if sensor signal was still detectable from inside the patient's body) for a follow-up period of 10 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: There is only one patient group. The one that swallow the sensor capsule.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule: A Pilot Study [DING]
Actual Study Start Date : April 11, 2015
Actual Primary Completion Date : February 24, 2016
Actual Study Completion Date : February 29, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Experimental: HemoPill acute

Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.

Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.

Diagnostic Test: HemoPill acute
Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.




Primary Outcome Measures :
  1. Number of Participants With (Serious) Adverse Event Related to the Medical Device [ Time Frame: until capsule excretion happened, an average of 10 days ]

    In this outcome measure the safety of the sensor capsule is evaluated in relation to the patient application.

    1. Every malfunction, failure or characteristic change or performance of the medical device as well as each inappropriate labeling or instruction for use, which can directly or indirectly lead to death or a serious advers event that deteriorates the physical health state of a patient, user or another person.
    2. Every technical or medical reason, which are a result of the causes mentioned in No.1 due to the characteristics or performance of the medical device.

  2. Number of Participants With Device Deficiencies [ Time Frame: until data of the receiver is saved, an average of 2 weeks ]
    All device deficiencies that appear in the study. In this outcome measure the safety and feasibility of the capsule is evaluated.

  3. Number of Participants With Human Failures in Capsule Application [ Time Frame: until capsule excretion happened, an average of 10 days ]
    Human failures that appear during the capsule application or data readout.

  4. Number of Participants With Sensor Capsule Ingestion Problems [ Time Frame: at time of capsule ingestion, 1 day ]
    In this outcome measure the feasibility of the capsule is evaluated and if patients have issues on swallowing the sensor capsule in respect to it's size, form or other reasons.

  5. Number of Patients Which do Not Accept the Medical Device, Measured in Numbers [ Time Frame: at time of study inclusion, 1 day ]
    Patients that have acceptance problems with the sensor capsule in respect to its size, form or other reasons.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical suspicion based on anamnestic statements and clinical symptom
  • vomiting of hematin (coffee-ground-like material)
  • hematemesis
  • melena (anamnestic or digital rectal evidence)
  • attentive and conscious patient
  • written informed consent, age ≥ 18 years and ≤ 80 years

Exclusion Criteria:

  • circulatory instability (with a clear need for urgent endoscopy)
  • cases which required urgently surgical therapy, e.g. patients previously treated endoscopically because of GI bleeding and with an urgent suspicion of recurrent bleeding, which could not be treated endoscopically because of previous findings as well as patients experiencing re-bleeding after surgery
  • known and assumed stenosis of the GI tract, e.g. patients with fistulas, malformations and anatomical variability, insufficiencies, adhesions and previous traumas
  • pacemakers or other implantable electrical devices
  • difficulties in swallowing pills the size of the capsule known dysphagia (e.g. achalasia, known diverticula of the esophagus etc.) which were inoperable: patients with ASA IV or higher
  • known and distinct retardation of the gastro-intestinal tract, induced by previous surgeries, stenosis or paralytic ileus with a diagnosed enteritis
  • moribund patient
  • pregnancy and breastfeeding
  • psychological illnesses, which might impair patient cooperation (comprehension problems, informed consent impossible)
  • stomach bezoar
  • NSAR-induced enteropathy
  • known allergies against Parylene (surface coating of the capsule)
  • peptic esophagitis III an IV
  • florid M.Crohn or known inflammation-induced strictures
  • distinct diverticulosis or diverticulitis
  • suspected gastrointestinal tumor disease
  • necessity of MRI investigation
  • heavy genetic bleeding tendency (e.g. factor VIII deficiency)
  • esophagus varices
  • class III obesity (BMI ≥ 40)
  • missing informed consent
  • age < 18 years and > 80 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03176407


Locations
Layout table for location information
Germany
Department of Gastroenterology and Oncology, Klinikum Ludwigsburg
Ludwigsburg, Germany
Sponsors and Collaborators
Ovesco Endoscopy AG
Investigators
Layout table for investigator information
Study Director: Thomas Gottwald, Prof. Dr. Ovesco Endoscopy AG
Publications of Results:
Layout table for additonal information
Responsible Party: Ovesco Endoscopy AG
ClinicalTrials.gov Identifier: NCT03176407    
Other Study ID Numbers: CT20-HPA-1401
First Posted: June 5, 2017    Key Record Dates
Results First Posted: October 10, 2019
Last Update Posted: October 10, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ovesco Endoscopy AG:
sensor capsule
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhage
Pathologic Processes